Quickcool AB: The rights issue subscribed to 67%
The subscription period in Quickcool’s rights issue with preferential rights for the company's shareholders is closed. The issue was subscribed to 67 per cent. The subscription amounts to SEK 4.3 million (of which SEK 2.2 million is added by offsetting), before deducting the issue costs, which are estimated at approximately SEK 0.3 million.
In total, 1 431 372 Units were subscribed, of which 659 409 Units were subscribed with the support of subscription rights and 771 963 Units without the support of subscription rights according to the subscription notifications. 1 000 000 Units have been subscribed by pre-made guarantees. Of these, 750 001 units have been subscribed by offsetting.
In number of shares, this corresponds to 4 294 116 shares, of which 2 315 889 were subscribed with the support of subscription rights and 2 315 889 without the support of subscription rights according to the subscription notifications. 3 000 000 shave been subscribed through pre-made guarantees.
The sales notes are expected to be sent out around the 21st of December with a settlement date around January 3, whereupon the registration will begin at the Swedish Companies Registration Office.
For additional information, please contact:
Fredrik Radencrantz, CEO
Phone: 046-286 38 40
E-mail: fredrik.radencrantz@quickcool.se
This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made publicly available by the Company’s contact person on 21 December, 2018.
QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund.
For more Information, please refer to www.quickcool.se
Tags: